[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
December 12, 2001

Cardiovascular Events and COX-2 Inhibitors

Author Affiliations

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;286(22):2808-2813. doi:10.1001/jama.286.22.2808

To the Editor: In their meta-analysis, Dr Mukherjee and colleagues1 found that cyclooxygenase 2 (COX-2) inhibitors might cause an increase in cardiovascular (CV) events. This may lead clinicians to avoid COX-2 inhibitors for their patients with arthritis. I believe that this conclusion is ill advised.

Other nonsteroidal anti-inflammatory drugs (NSAIDs) have been estimated to have a 1% to 4% annual rate of significant adverse events.2 The 2 large trials of COX-2 inhibitors, VIGOR (Vioxx Gastrointestinal Outcomes Research Study3) and CLASS (Celecoxib Arthritis Safety Study4), both found a 1% to 2% decline in serious gastrointestinal (GI) complications with the use of COX-2 inhibitors compared with other NSAIDs. In contrast, Mukherjee et al found a 0.24% and 0.3% increase in cardiovascular events for rofecoxib and celecoxib, respectively. Preventing about 3 CV events per thousand while increasing GI complications 10 to 20 per thousand may not be the most equitable trade.

First Page Preview View Large
First page PDF preview
First page PDF preview